Seres Therapeutics

decision difficult arrows think consider
Biotech

Seres slims R&D, staff to focus on approved microbiome drug

After securing an approval for a microbiome therapy, Seres is facing some tough choices, resulting in a restructuring that will claim 41% of staff.
Annalee Armstrong Nov 2, 2023 12:22pm
Parachute

Leaps by Bayer chief jumps to Bayer, too—Chutes & Ladders

Aug 25, 2023 9:30am
C difficile clostridium difficile

FDA mulls approving first oral microbiome therapy from Seres

Oct 26, 2022 9:55am
visual of gut bacteria

Equipped with new safety data, Seres eyes FDA approval

Jun 7, 2022 7:00am
S aureus infection

Seres Therapeutics' microbiome therapy flops against placebo

Jul 22, 2021 7:30am
Nestle

Nestlé, Seres re-up microbiome partnership in $175M deal

Jul 1, 2021 12:00pm